In a nutshell This study wanted to find out how well lurbinectedin (PM01183) works in treatment of breast cancer with BRCA1/2 mutations (abnormal genes), which has spread. The study found that lurbinectedin worked well in treating patients with BRCA1/2 mutated breast cancer which had spread. Some background BRCA1 and BRCA2 are genes that stop tumors...
Read More
In a nutshell This study wanted to find out how well lurbinectedin (PM01183) works in treatment of breast cancer with BRCA1/2 mutations (abnormal genes), which has spread. The study found that lurbinectedin worked well in treating patients with BRCA1/2 mutated breast cancer which had spread. Some background BRCA1 and BRCA2 are genes that stop tumors...
Read More
In a nutshell This study wanted to find out if shortening treatment for HER2-positive breast cancer with trastuzumab (Herceptin) from 1 year to 9 weeks would make the treatment less effective. The study found that treatment for nine weeks was not less effective than treatment for 1 year. Some background HER-2 positive breast cancer is a type of...
Read More
In a nutshell This article investigated the safety and effectiveness of myofascial release (MR) therapy on women survivors of breast cancer. The authors concluded that MR therapy is safe and resulted in physical benefits (overall shoulder movement, functionality, pain). Some background Surgery and radiation are among the main treatments for...
Read MoreIn a nutshell This study wanted to find out what benefits there were to doing electron radiation therapy during surgery alongside normal radiation therapy for women with breast cancer. The study found that ten years after surgery, almost all the patients who had electron radiotherapy during surgery had no reoccurrence of breast cancer. Some...
Read More
In a nutshell This study wanted to find out if ixabepilone (Ixempra) and capecitabine (Xeloda) work for treating triple-negative breast cancer in patients with hard to treat disease compared to using capecitabine alone. The study found that adding ixabepilone to treatment resulted in longer survival without the cancer progressing. Some background...
Read More
In a nutshell This article investigated the safety and effectiveness of adding Omega-3 fatty acid (O3-FA) to the management of joint pain in patients with breast cancer treated with aromatase inhibitors. The authors concluded that the addition of O3-FA is safe and gave the greatest benefit to patients who were obese. Some background...
Read More
In a nutshell This study wanted to find out which treatment is better for breast cancer, chemotherapy plus trastuzumab (Herceptin) and surgery, or pertuzumab (Perjeta), and chemotherapy plus trastuzumab (Herceptin) and surgery. The study found that adding pertuzumab to the standard treatment worked better to completely remove all signs of cancer compared...
Read More
In a nutshell This paper was looking at which type of therapy is best for women with breast cancer who are experiencing major depression. The study found that all three therapies tested resulted in equal benefit for the patients. Some background It is well known that there is an association between being diagnosed with breast cancer and...
Read More
In a nutshell This study wanted to find out if adding a medication called olanzapine (Zyprexa) to the current treatment methods helps reduce vomiting and nausea in patients with breast cancer who are receiving chemotherapy with anthracycline. The study found that adding in olanzapine to standard treatment helped reduce vomiting and nausea compared to...
Read More
In a nutshell This study wanted to find out which medication is better for treating HER-2 positive breast cancer, a class of medicines called anthracyclines plus trastuzmab (Herceptin) and pertuzmab (Perjeta), or carboplatin (Paraplatin) plus trastuzmab and pertuzmab. The study found that both medications worked equally as well as each other, but the...
Read More
In a nutshell This study wanted to see how well two medications worked in treating advanced triple negative breast cancer, atezolizumab (Tecentriq) and nab-paclitaxcel (Abraxane). The study found that using these two medications together improved survival in these patients. Some background Triple-negative breast cancer (TNBC) is breast cancer...
Read More
